Australia markets open in 2 hours 33 minutes

Aptinyx Inc. (APTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5650-0.0176 (-3.02%)
At close: 04:00PM EDT
0.5700 +0.00 (+0.88%)
After hours: 05:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5826
Open0.5800
Bid0.5510 x 4000
Ask0.5700 x 1800
Day's range0.5514 - 0.5900
52-week range0.5514 - 4.7300
Volume265,976
Avg. volume457,434
Market cap38.259M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Aptinyx to Participate in H.C. Wainwright Global Investment Conference

    EVANSTON, Ill., May 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.

  • Business Wire

    Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting

    EVANSTON, Ill., May 17, 2022--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.

  • Business Wire

    Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress

    EVANSTON, Ill., May 12, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2022 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.